相关实验视频

Updated: May 1, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

针对可切除食道状细胞癌的PET/CT导向新辅助药Tislelizumab加化学疗法/化学辐射疗法:RATIONALE-213最终分析

Yushang Yang¹, Xiaolong Yan², Hongjing Jiang³

¹West China Hospital of Sichuan University Sichuan China.

Clinical cancer research : an official journal of the American Association for Cancer Research

|March 2, 2026

概括

与化疗或化疗放射治疗相结合的tislelizumab显示了可切除食道状细胞癌 (ESCC) 的有希望的病理完整反应率. 这种新辅助治疗策略提供了有利的生存结果和可管理的安全性.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
胃肠道癌症胃肠道癌症

背景情况:

食道状细胞癌 (ESCC) 是一个重要的全球健康问题.
新辅助治疗旨在改善切除ESCC的手术结果和生存率.
定子发射断层扫描/计算机断层扫描 (PET/CT) 可以帮助评估治疗反应.

研究的目的:

为了评估tislelizumab加上PET/CT指导的化疗/化学放射治疗在可切除ESCC中的疗效和安全性.
为了确定由PET/CT反应分层的患者的病理完整响应 (pCR) 率.
评估生存结果和与治疗相关的不良事件.

主要方法:

一项多中心,开放的II期研究 (RATIONALE-213) 招募了70名可切除ESCC的患者.
患者接受了诱导化疗,然后被分为PET响应者或不响应者.
所有患者都接受了tislelizumab以及手术前的化疗 (响应者) 或化疗放射治疗 (不响应者).

主要成果:

病理完整响应 (pCR) 率在PET响应者中为30.0%,在PET无响应者中为34.4%.
较高的pCR率与较高的基线PD-L1瘤区域阳性 (TAP) 分数相关.
一年无病生存率分别为79.0%和74.2%,观察到可管理的安全性.

结论:

基于tislelizumab的新辅助疗法显示出可切除ESCC的PCR率和生存率有前途.
在PET/CT指导的响应者和非响应者中,治疗策略是可以容忍的.
这种方法需要进一步研究可切除ESCC治疗.

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.